Clinical Trials
13 trialsNCT03578367 2026-04-21
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Phase 2 Completed
NCT00769327 2022-01-04
CML0408
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00980018 2021-07-01
MACS0999
Novartis
Phase 4 Completed
NCT01844765 2021-04-22
DIALOG
Novartis
Phase 2 Completed
NCT00471497 2020-11-18
ENESTnd
Novartis
Phase 3 Completed
NCT02272777 2019-08-19
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Novartis
Phase 3 Completed
NCT00809211 2018-07-24
Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Cancer Trials Ireland
Phase 2 Completed
NCT01061177 2017-02-24
'MACS1252
Novartis
Phase 4 Completed
NCT00786812 2017-02-23
MACS0439
Novartis
Phase 4 Completed
NCT00760877 2016-11-08
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
Novartis
Phase 3 Completed
NCT01227577 2016-02-08
MACS1428
Novartis
Phase 4 Completed
NCT00802841 2015-11-16
LASOR
Novartis
Phase 3 Completed
NCT01819389 2014-01-07
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
Hospital Universitario Dr. Jose E. Gonzalez
Phase 3 Completed